Nic Lochlainn Consulting Ltd was founded by Dr Eimear Nic Lochlainn in 2007, prior to which Eimear had fifteen years of experience in global clinical development and market access strategies within the pharmaceutical and biotechnology industries. Eimear's work with Novartis, Pfizer, Sandoz and Virco-Tibotec, has taken her across the UK, Switzerland and Ireland.
After receiving her Ph.D. from Queen’s University Belfast in 1991, Eimear began her career as a statistician before retraining as a health economist at Stockholm University and University of London. She has worked on drug development programmes, from early development to post-launch (Phases I-IV) and on market access strategies to support product reimbursement. Eimear has also been an economic assessor and statistical advisor to the Scottish Medicines Consortium (SMC), critically appraising submissions from the pharmaceutical industry, seeking a positive reimbursement decision for new drugs.
Eimear has led Health Technology Assessments (HTAs) for the UK’s National Health Service (NHS) and contextualised NICE multiple technology assessments (MTAs) for endorsement in Scotland. As well as this and her extensive industry experience, Eimear Nic Lochlainn has been a visiting fellow at the University of Los Angeles, California (UCLA), working on the renal transplantation programme. She is also a guest lecturer on the Masters in Bioscience Enterprise (MBE) at Cambridge University.
K Sparrowhawk, Partner
...exceptional expertise...She has a can-do attitude, delivers quality work and is an absolute pleasure to work with.